RNA 분석 시장 - 산업 규모, 점유율, 동향, 기회, 예측 : 제품별, 기술별, 용도별, 최종 용도별, 지역별 및 경쟁(2021-2031년)

The Global RNA Analysis Market is projected to expand significantly, rising from USD 10.12 Billion in 2025 to USD 17.77 Billion by 2031, demonstrating a compound annual growth rate of 9.84%. This market involves technologies for identifying and sequencing ribonucleic acid molecules to understand gene expression and cellular behavior. Growth is primarily driven by the increasing emphasis on precision medicine and accelerated drug discovery, both of which require comprehensive transcriptomic profiling. Ongoing enhancements in sequencing throughput and accuracy also promote the adoption of these tools in clinical research, as evidenced by 38 new RNA therapy trials initiated in Q2 2025, according to the American Society of Gene & Cell Therapy. However, the sector grapples with the significant challenge of bioinformatic complexity, where the sheer volume of data from modern platforms often overwhelms standard laboratory processing capabilities, leading to costly delays in interpretation and creating a barrier for smaller institutions without adequate computational resources, thus impeding market expansion.

Market Driver

The market for RNA analysis is primarily driven by the growing number of RNA-based therapeutics and mRNA vaccines in development, shifting the analytical focus from genomic DNA to dynamic transcriptomics. As biopharmaceutical research expands into areas like oncology and rare genetic disorders, the need for stringent analytical quality control, covering aspects such as sequence identity and capping efficiency, has become critical. This heightened R&D activity fuels demand for high-precision assays capable of validating emerging modalities like circular RNA and siRNA, with over 3,200 global clinical trials reported in Q3 2025 by the American Society of Gene & Cell Therapy. Additionally, advancements in next-generation sequencing and high-throughput analysis are propelling market expansion by overcoming previous limitations in cost and throughput. Innovations in sequencing chemistry and platform design now enable laboratories to achieve deeper transcriptomic insights more rapidly and affordably, as exemplified by Pacific Biosciences' SPRQ-Nx chemistry, which is projected to reduce sequencing costs by up to 40%. This enhanced accessibility is evident in the broader adoption of specialized tools, such as the 19% increase in spatial consumables revenue for 10x Genomics in Q3 2025, indicating a rising dependence on advanced platforms for intricate tissue analysis.

Market Challenge

A significant obstacle to the Global RNA Analysis Market's growth is the bioinformatic complexity involved in processing extensive transcriptomic data. Modern high-throughput sequencing platforms produce increasingly vast datasets, often overwhelming standard laboratory infrastructure's storage and computational capabilities. This technological disparity creates a critical bottleneck where the sheer volume of raw data exceeds researchers' capacity to extract meaningful biological insights, leading to operational delays in drug discovery and clinical validation. This analytical hurdle disproportionately affects smaller research institutions and emerging biotechnology companies lacking the financial resources for high-performance computing or dedicated data science expertise. Their inability to process complex datasets efficiently restricts the broader adoption of advanced RNA analysis tools, thus limiting the market's overall reach. The challenge is intensified by the considerable clinical activity globally, with over 3,200 trials underway as of November 2025, according to the American Society of Gene & Cell Therapy, each contributing to the immense data load that strains current analytical capacities.

Market Trends

The Global RNA Analysis Market is being transformed by the integration of artificial intelligence (AI) and machine learning (ML) into bioinformatics, which addresses previous data analysis bottlenecks hindering clinical adoption. Research laboratories are increasingly utilizing AI-driven predictive models to link intricate transcriptomic datasets with clinical outcomes, thus accelerating the development of precision oncology and personalized therapies. This shift from manual data curation to algorithmic interpretation is reflected in the significant financial growth of companies focused on AI-enhanced genomic profiling, such as Tempus AI's Genomics division, which saw a 24.4% year-over-year revenue increase to $451.7 million in fiscal year 2024. This growth highlights the industry's increasing dependence on computational platforms to convert raw sequencing data into valuable biological insights. Concurrently, the market is experiencing a notable convergence of transcriptomics with proteomics, spurred by spatial biology technologies that map gene expression within the architectural context of tissues. This multi-omics strategy enables researchers to combine RNA sequencing data with protein markers, uncovering cellular interactions and microenvironmental details that single-cell dissociation methods cannot capture. The commercial strength of this segment is growing as pharmaceutical companies incorporate spatial profiling tools into their drug safety and efficacy studies, with Bio-Techne's Diagnostics and Spatial Biology segment revenue rising 6% to $346.3 million for fiscal year 2025, indicating ongoing demand for platforms that maintain spatial context. This trend signifies the sector's progression from basic sequence identification to sophisticated, spatially resolved tissue characterization.

Key Market Players

• Agilent Technologies, Inc.
• F. Hoffmann-La Roche Ltd
• Illumina, Inc.
• QIAGEN NV
• Thermo Fisher Scientific, Inc.
• Eurofins Scientific
• Merck KgaA
• Bio-Rad Laboratories, Inc.
• Pacific Bioscience of California, Inc.
• Affymetrix, Inc.

Report Scope

In this report, the Global RNA Analysis Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

RNA Analysis Market, By Product

• Kits & Reagents
• Services
• Instruments

RNA Analysis Market, By Technology

• Real Time-PCR (qPCR)
• Microarray
• Sequencing
• others

RNA Analysis Market, By Application

• Epigenetics
• Infectious Diseases & Pathogenesis
• Alternative RNA Splicing
• RNA Structure & Molecular Dynamics
• Development & Delivery of RNA Therapeutics

RNA Analysis Market, By End-use

• Government Institutes & Academic Centers
• Pharmaceutical & Biotechnology Companies
• Hospitals & Clinics
• others

RNA Analysis Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global RNA Analysis Market.

Available Customizations:

Global RNA Analysis Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global RNA Analysis Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Product (Kits & Reagents, Services, Instruments)
  • 5.2.2. By Technology (Real Time-PCR (qPCR), Microarray, Sequencing, others)
  • 5.2.3. By Application (Epigenetics, Infectious Diseases & Pathogenesis, Alternative RNA Splicing, RNA Structure & Molecular Dynamics, Development & Delivery of RNA Therapeutics)
  • 5.2.4. By End-use (Government Institutes & Academic Centers, Pharmaceutical & Biotechnology Companies, Hospitals & Clinics, others)
  • 5.2.5. By Region
  • 5.2.6. By Company (2025)
• 5.3. Market Map

6. North America RNA Analysis Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Product
  • 6.2.2. By Technology
  • 6.2.3. By Application
  • 6.2.4. By End-use
  • 6.2.5. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States RNA Analysis Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Product
      • 6.3.1.2.2. By Technology
      • 6.3.1.2.3. By Application
      • 6.3.1.2.4. By End-use
  • 6.3.2. Canada RNA Analysis Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Product
      • 6.3.2.2.2. By Technology
      • 6.3.2.2.3. By Application
      • 6.3.2.2.4. By End-use
  • 6.3.3. Mexico RNA Analysis Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Product
      • 6.3.3.2.2. By Technology
      • 6.3.3.2.3. By Application
      • 6.3.3.2.4. By End-use

7. Europe RNA Analysis Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Product
  • 7.2.2. By Technology
  • 7.2.3. By Application
  • 7.2.4. By End-use
  • 7.2.5. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany RNA Analysis Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Product
      • 7.3.1.2.2. By Technology
      • 7.3.1.2.3. By Application
      • 7.3.1.2.4. By End-use
  • 7.3.2. France RNA Analysis Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Product
      • 7.3.2.2.2. By Technology
      • 7.3.2.2.3. By Application
      • 7.3.2.2.4. By End-use
  • 7.3.3. United Kingdom RNA Analysis Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Product
      • 7.3.3.2.2. By Technology
      • 7.3.3.2.3. By Application
      • 7.3.3.2.4. By End-use
  • 7.3.4. Italy RNA Analysis Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Product
      • 7.3.4.2.2. By Technology
      • 7.3.4.2.3. By Application
      • 7.3.4.2.4. By End-use
  • 7.3.5. Spain RNA Analysis Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Product
      • 7.3.5.2.2. By Technology
      • 7.3.5.2.3. By Application
      • 7.3.5.2.4. By End-use

8. Asia Pacific RNA Analysis Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Product
  • 8.2.2. By Technology
  • 8.2.3. By Application
  • 8.2.4. By End-use
  • 8.2.5. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China RNA Analysis Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Product
      • 8.3.1.2.2. By Technology
      • 8.3.1.2.3. By Application
      • 8.3.1.2.4. By End-use
  • 8.3.2. India RNA Analysis Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Product
      • 8.3.2.2.2. By Technology
      • 8.3.2.2.3. By Application
      • 8.3.2.2.4. By End-use
  • 8.3.3. Japan RNA Analysis Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Product
      • 8.3.3.2.2. By Technology
      • 8.3.3.2.3. By Application
      • 8.3.3.2.4. By End-use
  • 8.3.4. South Korea RNA Analysis Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Product
      • 8.3.4.2.2. By Technology
      • 8.3.4.2.3. By Application
      • 8.3.4.2.4. By End-use
  • 8.3.5. Australia RNA Analysis Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Product
      • 8.3.5.2.2. By Technology
      • 8.3.5.2.3. By Application
      • 8.3.5.2.4. By End-use

9. Middle East & Africa RNA Analysis Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Product
  • 9.2.2. By Technology
  • 9.2.3. By Application
  • 9.2.4. By End-use
  • 9.2.5. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia RNA Analysis Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Product
      • 9.3.1.2.2. By Technology
      • 9.3.1.2.3. By Application
      • 9.3.1.2.4. By End-use
  • 9.3.2. UAE RNA Analysis Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Product
      • 9.3.2.2.2. By Technology
      • 9.3.2.2.3. By Application
      • 9.3.2.2.4. By End-use
  • 9.3.3. South Africa RNA Analysis Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Product
      • 9.3.3.2.2. By Technology
      • 9.3.3.2.3. By Application
      • 9.3.3.2.4. By End-use

10. South America RNA Analysis Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Product
  • 10.2.2. By Technology
  • 10.2.3. By Application
  • 10.2.4. By End-use
  • 10.2.5. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil RNA Analysis Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Product
      • 10.3.1.2.2. By Technology
      • 10.3.1.2.3. By Application
      • 10.3.1.2.4. By End-use
  • 10.3.2. Colombia RNA Analysis Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Product
      • 10.3.2.2.2. By Technology
      • 10.3.2.2.3. By Application
      • 10.3.2.2.4. By End-use
  • 10.3.3. Argentina RNA Analysis Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Product
      • 10.3.3.2.2. By Technology
      • 10.3.3.2.3. By Application
      • 10.3.3.2.4. By End-use

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global RNA Analysis Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Agilent Technologies, Inc.
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. F. Hoffmann-La Roche Ltd
• 15.3. Illumina, Inc.
• 15.4. QIAGEN NV
• 15.5. Thermo Fisher Scientific, Inc.
• 15.6. Eurofins Scientific
• 15.7. Merck KgaA
• 15.8. Bio-Rad Laboratories, Inc.
• 15.9. Pacific Bioscience of California, Inc.
• 15.10. Affymetrix, Inc.

16. Strategic Recommendations

17. About Us & Disclaimer